newsfilter
← Latest News
GlobeNewswire·

Biodexa provides R&D Update

November 9, 2026 Biodexa provides R&D Update Phase 3 Serenta trial in FAP is now two-thirds recruited Preparations advanced for Phase 1 trial of MTX240 in GIST Biodexa Pharmaceuticals PLC (NASDAQ:BDRX)